Safety and Efficacy Study of XPF-001 to Treat Pain Following Wisdom Tooth Extraction

Completed · Phase 2 · Has a placebo group

Conditions studied: Dental Pain

In brief

The purpose of this trial is to determine if XPF-001 is effective for the treatment of pain following third-molar/wisdom tooth extraction.

Key facts

Study ID

NCT00954356

Run by

Xenon Pharmaceuticals Inc.

People needed

61

Starts

2009-09-01

Expected to finish

2009-12-01

Last updated by the study team

2012-07-16

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Males (aged 18-60) and females of non-childbearing potential (aged 18-60;
• BMI between 19.5 to 32.0 kg/m2;
• Outpatient, scheduled to undergo surgical extraction of 2 or more impacted 3rd molars (with at least 1 partial bony mandibular extraction);
• use of only the following preoperative medications 2% lidocaine with epinephrine and nitrous oxide;
• Able to complete the requested information on analgesic questionnaires and able to comply with study procedures and restrictions;
• Able to read, comprehend and sign the consent form;
• Deemed medically healthy to participate in the study, with normal or clinically insignificant medical history, physical examination, lab tests and ECG results;
• No contraindications to the study drug, it excipients or any of the study medications including rescue medications.

You may not qualify if…

• Presence of a clinically significant medical condition;
• Positive test for HIV, Hepatitis B or Hepatitis C;
• Use of any prescription or over the counter medication or supplement in the 48 hours before dose of study drug until discharge;
• Acute local infection at the time of dental surgery;
• Females who are pregnant, lactating or of child-bearing potential, or who provide a positive pregnancy test result at screening or check-in;
• Males not undertaking adequate measures to prevent their partner becoming pregnant throughout the study;
• Clinically significant laboratory values;
• Clinically significant abnormal ECG;
• History or presence of alcoholism, or alcohol or substance abuse (within previous 2 years), or routine consumption of 3 or more alcoholic drinks per day;
• A positive urine drug test;
• Routine use of analgesics 5 or more times per week;
• Presence or history (within 2 years of enrolment) of bleeding disorder(s) or peptic ulcer disease;
• History of allergic reaction to any drug, including penicillin;
• Ingestion of caffeine containing foods or drinks in the 24 hours before dose of study drug;
• Consumption of alcohol in the 48 hours before dose of study drug, or a positive alcohol breath test at check-in;
• Consumption of grapefruit or grapefruit containing products in the 7 days before dose of study drug;
• Use of tobacco or nicotine substitutes within 1 month of dose of study drug, or inability to refrain from use of nicotine between check-in and follow up;
• Treatment for depression in the 6 months prior to enrolment;
• Use of another investigational drug in the 60 days before enrolment;
• Donation or loss of 50-500 mL of blood in the 30 days prior to enrolment, or more than 500 mL of blood in the 56 days before enrolment;
• Previously entered into this study;
• Study site or Sponsor employees or relatives of employees directly involved in the study;
• Any other condition that (in the opinion of the Investigator or sponsor) makes the subject unsuitable for the study.

Where it is running

• Jean Brown Research — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.